Table 2

Cox regression analysis of immunohistochemistry signature score and clinicopathological covariates with survivals in the Shanghai cohort

	Disease-free survival				Disease-specific survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
Signature score (high-risk vs low-risk)	4.50 (3.10 to 6.54)	<0.001	4.55 (3.07 to 6.76)	<0.001	6.47 (3.72 to 11.26)	<0.001	6.62 (3.70 to 11.85)	<0.001
TNM stage (III vs I+II)	2.62 (1.78 to 3.85)	<0.001	1.69 (1.10 to 2.60)	0.018	2.11 (1.25 to 3.55)	0.005	1.40 (0.78 to 2.50)	0.262
Differentiation grade (poorly vs well+moderately)	1.99 (1.37 to 2.90)	<0.001	1.47 (0.99 to 2.19)	0.057	1.95 (1.17 to 3.28)	0.011	1.52 (0.88 to 2.63)	0.132
Adjuvant chemotherapy (yes vs no)	3.70 (1.63 to 8.41)	0.002	1.81 (0.75 to 4.42)	0.189	2.77 (1.00 to 7.64)	0.049	1.54 (0.51 to 4.67)	0.448
Age (≥50 vs < 50 years)	0.71 (0.47 to 1.06)	0.096	0.79 (0.50 to 1.23)	0.292	1.16 (0.60 to 2.22)	0.663	1.23 (0.61 to 2.46)	0.561
Sex (men vs women)	1.18 (0.81 to 1.71)	0.386	1.25 (0.84 to 1.85)	0.277	1.34 (0.79 to 2.27)	0.275	1.36 (0.78 to 2.36)	0.278
Disease location (rectum vs colon)	1.05 (0.73 to 1.51)	0.788	1.25 (0.85 to 1.84)	0.254	1.22 (0.73 to 2.02)	0.446	1.33 (0.78 to 2.27)	0.293
Lymph nodes examined (≥12 vs <12)	2.09 (1.42 to 3.07)	<0.001	1.90 (1.26 to 2.85)	0.002	1.88 (1.11 to 3.20)	0.020	1.95 (1.12 to 3.40)	0.019
Serum CEA (ng/ml) (≥ 5 vs <5)	1.35 (0.94 to 1.95)	0.110	1.02 (0.68 to 1.53)	0.939	1.36 (0.81 to 2.26)	0.242	1.01 (0.58 to 1.76)	0.968
Serum CA19-9 (U/ml) (≥ 37 vs <37)	1.85 (1.21 to 2.83)	0.004	1.63 (1.00 to 2.64)	0.049	1.71 (0.94 to 3.10)	0.080	1.50 (0.77 to 2.92)	0.230

CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; TNM, tumour to node to metastasis.